Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, 10 november Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Human medicines European public assessment report (EPAR): Ocrevus, ocrelizumab, Multiple Sclerosis, Date of authorisation: 08/01/2018, Revision: 18, Status: Authorised Lees verder » Wil je het laatste nieuws in jouw mailbox? Meld je dan aan voor de nieuwsbrief.